Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALON trial of brolucizumab versus aflibercept in neovascular age-related macular degeneration
NL-OMON49739Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in exudative macular degeneration comparing Brolucizumab arm with Aflibercept arm (2 arms). Primary endpoints: Treatment interval duration at Week 32 and Average change in BCVA from baseline at Weeks 28 and 32. Started Oct 2019; status: active, not recruiting.
02
Drugs
brolucizumabaflibercept
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON49739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49739.